Racial Differences Seen in Pain Rx for Older Adults With Hip Fracture
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 12, 2024 -- Racial differences exist in opioid pain management for Medicare beneficiaries after a hip fracture, according to a study published online Sept. 11 in the Journal of the American Geriatrics Society.
Kaleen N. Hayes, Pharm.D., Ph.D., from Brown University in Providence, Rhode Island, and colleagues assessed whether the receipt and dose of opioids differed between Black and White older adult U.S. Medicare beneficiaries with a hip fracture as they transitioned back to the community setting. The analysis included 164,170 older adults (mean age, 82.7 years) with hip fracture.
The researchers found that overall use of opioids in the community was similar between Black and White Medicare beneficiaries. However, Black beneficiaries had lower average doses in their first 90 days in both total cumulative doses (institutional postacute care [PAC] group, 165 fewer milligram morphine equivalents [MMEs]; no PAC, 167 fewer MMEs) and average MME per days' supply of medication (PAC, –3.0 fewer MMEs per day; no PAC, –4.7 fewer MMEs per day). In secondary analyses, the greatest differences were seen among Asian beneficiaries (e.g., 617 to 653 fewer cumulative mg oxycodone).
“Future work should examine whether these differences result in disparities in short- and long-term health outcomes,” the authors write.
Several authors disclosed ties to relevant organizations.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-13 06:00
Read more
- Lower Risk for Asthma Seen With Younger Age at Natural Menopause
- Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
- Skin Patch Uses 'Imperceptible' Electric Zaps to Heal Wounds Without Drugs
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
- New Combo Drug Therapy Halves Death Risk From Advanced Hodgkin Lymphoma
- Bidirectional Link Seen for Rheumatoid Arthritis, Interstitial Lung Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions